DOI QR코드

DOI QR Code

Two-Year Clinical Outcome after Carvedilol-Loaded Stent Implantation in Patients with Coronary Artery Disease

  • Kim, Hyun-Kuk (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Hong, Young-Joon (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Jeong, Myung-Ho (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Kim, Weon (Cardiovascular Division, Department of Internal Medicine, Kyung Hee University Medical Hospital) ;
  • Kim, Sung-Soo (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Ko, Jum-Suk (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Lee, Min-Goo (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Sim, Doo-Sun (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Park, Keun-Ho (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Yoon, Nam-Sik (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Yoon, Hyun-Ju (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Kim, Kye-Hun (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Park, Hyung-Wook (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Kim, Ju-Han (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Ahn, Young-Keun (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Cho, Jeong-Gwan (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Park, Jong-Chun (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital) ;
  • Kang, Jung-Chaee (Department of Internal Medicine, The Heart Center of Chonnam National University Hospital)
  • Published : 2011.03.01

Abstract

Background/Aims: Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration. The aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes after stent implantation in patients with coronary artery disease. Methods: We performed a prospective trial with male subjects to compare the safety and effects of carvedilol-loaded $BiodivYsio^{(R)}$ stents implanted into 20 patients with those of bare-metal $BiodivYsio^{(R)}$ stents implanted into 21 patients for de novo coronary lesions. The primary end point was the degree of neointimal hyperplasia, which was measured by intravascular ultrasound (IVUS) 6 months after the procedure; the secondary end point was major adverse cardiac events (MACE) at 2 years after implantation. All carvedilol and control stents were deployed successfully. Results: A 2-year follow-up was completed for 19 patients (95%) in the carvedilol stent group and 20 patients (95%) in the control stent group. IVUS showed a trend toward a larger luminal area (6.86 ${pm}$ 2.59 vs. 5.47 ${pm}$ 1.52 $mm^2$, p = 0.267), smaller neointimal area (1.34 ${pm}$ 0.70 vs. 2.40 ${pm}$ 1.73$mm^2$, p = 0.18), and reduced net decrease in luminal area (-0.78 ${pm}$ 0.97 vs. -1.89 ${pm}$ 1.78 $mm^2$, p = 0.106) in the carvedilol stent group compared with the control stent group, respectively. There were no significant differences in the incidence of MACE (10.5 vs. 30.0%, respectively, p = 0.132) between the groups at 2 years after stent implantation. Stent thrombosis did not occur in either group after 2 years. Conclusions: The carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of cardiac death, myocardial infarction, or stent thrombosis at 2-year follow-up.

Keywords

References

  1. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-163. https://doi.org/10.1016/S0735-1097(99)00486-6
  2. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52. https://doi.org/10.1161/01.CIR.99.1.44
  3. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230. https://doi.org/10.1016/S0735-1097(98)81613-6
  4. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-98.
  5. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993;90:6189-6193. https://doi.org/10.1073/pnas.90.13.6189
  6. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993;21:221-227. https://doi.org/10.1097/00005344-199302000-00006
  7. Park J, Ha H, Kim MS, Ahn HJ, Huh KH, Kim YS. Carvedilol inhibits platelet-derived growth factor-induced extracellular matrix synthesis by inhibiting cellular reactive oxygen species and mitogen-activated protein kinase activation. J Heart Lung Transplant 2006;25:683-689. https://doi.org/10.1016/j.healun.2006.01.008
  8. Kim W, Jeong MH, Cha KS, et al. Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ J 2005;69:101-106. https://doi.org/10.1253/circj.69.101
  9. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  10. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545. https://doi.org/10.1056/NEJMoa021007
  11. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323. https://doi.org/10.1056/NEJMoa035071
  12. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997. https://doi.org/10.1056/NEJMoa066633
  13. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-1061. https://doi.org/10.1016/j.amjmed.2006.01.023
  14. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 2009;73:615-621. https://doi.org/10.1253/circj.CJ-09-0059
  15. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058. https://doi.org/10.1161/CIRCULATIONAHA.106.675934
  16. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17 Suppl B:24-29. https://doi.org/10.1093/eurheartj/17.suppl_B.24
  17. Tanous D, Brasen JH, Choy K, et al. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. Atherosclerosis 2006;189:342-349. https://doi.org/10.1016/j.atherosclerosis.2006.01.025

Cited by

  1. A Critical Review of the Use of Carvedilol in Ischemic Heart Disease vol.12, pp.6, 2011, https://doi.org/10.1007/bf03262473
  2. Use of carvedilol in hypertension: an update vol.8, pp.None, 2012, https://doi.org/10.2147/vhrm.s31578
  3. Study on prescriptions for pregnancy and childbirth of the royal family in Joseon dynasty vol.15, pp.4, 2011, https://doi.org/10.1007/s13596-015-0208-4
  4. Development of Novel Drug-Eluting Stents for Acute Myocardial Infarction vol.53, pp.3, 2017, https://doi.org/10.4068/cmj.2017.53.3.187